--- title: "Sino Biopharm Wins FDA IND Nod for Pan-KRAS Cancer Drug TQB3205" type: "News" locale: "en" url: "https://longbridge.com/en/news/282119054.md" description: "Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, has received FDA approval for TQB3205, an oral pan-KRAS inhibitor targeting advanced malignant tumors. This drug aims to address a wider range of KRAS mutations, which are linked to about 30% of cancers globally. The company is expanding its oncology portfolio, complementing its existing G12C inhibitor, Garsorasib. Analysts rate Sino Biopharmaceutical (HK:1177) as a Buy with a price target of HK$8.70. The company focuses on innovative drug development in oncology and other therapeutic areas, with a market cap of HK$113.2B." datetime: "2026-04-08T23:37:06.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282119054.md) - [en](https://longbridge.com/en/news/282119054.md) - [zh-HK](https://longbridge.com/zh-HK/news/282119054.md) --- # Sino Biopharm Wins FDA IND Nod for Pan-KRAS Cancer Drug TQB3205 ### Easter Sale - 70% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Sino Biopharmaceutical ( (HK:1177) ) has shared an update. Sino Biopharmaceutical said its subsidiary Chia Tai Tianqing has secured U.S. FDA clearance for an investigational new drug application for TQB3205, an oral pan-KRAS inhibitor for advanced malignant tumors. The molecule is designed to bind multiple KRAS-mutant proteins with high affinity, locking them in an inactive state and blocking downstream signaling pathways such as MAPK and PI3K-AKT to curb proliferation of KRAS-mutant tumor cells. KRAS mutations are implicated in about 30% of cancers worldwide, including high rates in pancreatic, colorectal and non-small cell lung cancers, yet currently approved KRAS drugs only target the G12C subtype. By advancing TQB3205, which aims to address a broader spectrum of KRAS mutations, alongside its already approved G12C inhibitor Garsorasib in China, Sino Biopharmaceutical is deepening its strategic footprint in KRAS-targeted oncology and positioning itself to serve a wider patient population with significant unmet needs. The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page. **More about Sino Biopharmaceutical** Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group engaged in the research, development and commercialization of innovative drugs. Through subsidiaries such as Chia Tai Tianqing Pharmaceutical Group, the company focuses on oncology and other high-incidence therapeutic areas, with a growing portfolio of targeted therapies aimed at major unmet medical needs. **Average Trading Volume:** 69,787,707 **Technical Sentiment Signal:** Buy **Current Market Cap:** HK$113.2B For an in-depth examination of 1177 stock, go to TipRanks’ Overview page. ### Related Stocks - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [44080.HK](https://longbridge.com/en/quote/44080.HK.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [159929.CN](https://longbridge.com/en/quote/159929.CN.md) - [589720.CN](https://longbridge.com/en/quote/589720.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [01177.HK](https://longbridge.com/en/quote/01177.HK.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) ## Related News & Research - [GenFleet Asserts Independent IP for Pan RAS Inhibitor GFH276 Amid Sector Dispute](https://longbridge.com/en/news/284312081.md) - [Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation | ONNVF Stock News](https://longbridge.com/en/news/285274936.md) - [Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate](https://longbridge.com/en/news/284532331.md) - [Grand Pharmaceutical Moves to Adopt New Bye-Laws Aligned With HK Paperless Regime](https://longbridge.com/en/news/284576690.md) - [ZAWYA: Emirates Drug Establishment approves first nasal epinephrine spray as alternative to injections for severe allergic reaction](https://longbridge.com/en/news/284603051.md)